<DOC>
	<DOC>NCT01134523</DOC>
	<brief_summary>To compare the efficacy and safety of EC-T and ET regimen as adjuvant treatment of breast cancer patients with positive lymph nodes</brief_summary>
	<brief_title>Regimens Comparison for Breast Cancers of Positive Lymph Nodes</brief_title>
	<detailed_description>EC-T regimen: epirubicin 90mg/m2 day1, CTX 600mg/m2, day 1, 21 days per cycle *4cycle. followed by paclitaxel 175mg/m2,d1,21days per cycle, 4 cycle. ET regimen: epirubicin 75mg/m2 day1,paclitaxel 175mg/m2,d2,21days per cycle, 6 cycle</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>patients with breast cancer after breast cancer surgery with positive lymph nodes age 1870 years old with other malignance disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>positive lymph node</keyword>
</DOC>